:신규 등재 예정인 약제로 국내·외 허가사항, 교과서, 임상진료지침, 임상논문 등을 참조하여 허가사항 범위 내에서 투여 시 급여 인정함.
■ 관련문헌 등(*필요시 생략 가능)
· Harrison's Principles of Internal Medicine, 19e. 2015.
· Manual of Clinical Psychopharmacology, 8th Edition. 2015.
· NICE, Psychosis and schizophrenia in adults: prevention and management, 2014.02
· SIGN 131, Management of schizophrenia, 2013.03
· Meta-guidelines for the management of patients with schizophrenia, CNS Spectrums, 2013
· Long-acting injectable antipsychotics : recommendations for clinicians, Can J Psychiatry, 2013
· French Association for Biological Psychiatry and Neuropsychopharmacology (AFPBN) Guideline, 2013
· Ishigooka J et al., Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: a multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole. Schizophrenia Research. 2015 Feb;161(2-3):421-8.
· Kane J.M. et al., Aripiprazole once-monthly in the acute treatment of schizophrenia: Findings from a 12-week, randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry. 2014 Nov;75(11):1254-60.
· Kane J.M. et al., Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry. 2012 May;73(5):617-24.
· Naber D et al., Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. Schizophrenia Research. 2015 Oct;168(1-2):498-504.